GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Inventories, Other

Oxurion NV (XBRU:OXUR) Inventories, Other : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Oxurion NV's other inventories for the quarter that ended in Dec. 2023 was €0.00 Mil.


Oxurion NV Inventories, Other Historical Data

The historical data trend for Oxurion NV's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Inventories, Other Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oxurion NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.05 - - -

Oxurion NV Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Oxurion NV (XBRU:OXUR) Business Description

Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines